Antiresorptive Therapy in Hyperthyroid Patients: Longitudinal Changes in Bone and Mineral Metabolism

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 6, 1997, Pages 1989-1994

  Jódar, Esteban ^d   Muñoz Torres, Manuel ^c   Escobar Jiménez, Fernando ^e   Quesada, Miguel ^e   Luna, Juan D ^b   Olea, Nicolas ^a  

^a University Hospitals   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c University Hospital 12 de Octubre ^*  (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CARBIMAZOLE;

ADULT; ANIMAL; ARTICLE; BONE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HYPERTHYROIDISM; INTRANASAL DRUG ADMINISTRATION; LONGITUDINAL STUDY; MALE; OSTEOLYSIS; PROSPECTIVE STUDY; RADIODENSITOMETRY; RANDOMIZED CONTROLLED TRIAL; SALMON; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADULT; ANIMALS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CALCITONIN; CARBIMAZOLE; DENSITOMETRY, X-RAY; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTHYROIDISM; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; SALMON; TREATMENT OUTCOME;

EID: 0031159059     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.82.6.4026     Document Type: Article

References (27)

1. Fraser WD, Anderson JB, Smith DA, Wilson GM. 1971 Osteoporosis and fractures following thyrotoxicosis. Lancet. 1:981-983.
2. Riggs BL, Melton III LJ. 1992 The prevention and treatment of osteoporosis. N Engl J Med. 327:620-627.
3. Eriksen EF. 1986 Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev. 7:379-410.
4. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. 1994 Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab. 78:955-959.
5. Toh SH, Claunch BC, Brown. 1985 Effect of hyperthyroidism and its treatment on bone mineral content. Arch Intern Med. 145:883-891.
6. Lee MS, Kim SY, Lee MC, et al. 1990 Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J Clin Endocrinol Metab. 70:766-770.
7. Campos Pastor MM, Muñoz-Torres M, Escobar-Jiménez F, Ruiz de Almodovar M, Jodar E. 1993 Bone mass in females with different thyroid disorders: influence of menopausal status. Bone Miner. 21:1-8.
8. Wakasugi M, Wakao R, Tawata M, Gan N, Koizumi K, Onaya T. 1993 Bone mineral density in patients with hyperthyroidism measured by dual energy x-ray absorptiometry. Clin Endocrinol (Oxf). 38:283-286.
9. Hansen MA, Hassager C, Overgaard K, Marslew U, Riis B, Christiansen C. 1990 Dual-energy x-ray absorptiometry: a precise method of measuring bone mineral density in the lumbar spine. J Nucl Med. 31:1156-1162.
10. Cummings SR, Black DM, Nevitt MC, et al. 1993 Bone density at various sites for prediction of hip fractures. Lancet. 341:72-75.
11. Eriksen EF, Brixen K, Charles P. 1995 New markers of bone metabolism: Clinical use in metabolic bone disease. Eur J Endocrinol. 132:251-263.
12. McLeod JM, McHardy KC, Harvey RD, et al. 1993 The early effects of radioiodine theraphy for hyperthyroidism on biochemical indices of bone turnover. Clin Endocrinol (Oxf). 38:49-53.
13. Langdahl BL, Loft AGR, Eriksen EF, Mosekilde L, Charles P. 1996 Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid. 6:161-168.
14. Rosen CL, Adler RA. 1992 Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab. 75:1531-1534.
15. Diamond T, Vine J, Smart R, Butler P. 1994 Thyrotoxic bone disease in women: a potentially reversible disorder. Ann Intern Med. 120:8-11.
16. Cooper DS. 1988 Thyroid hormones and the skeleton: a bone of contention. JAMA. 259:3175.
17. Baran DT, Braverman LE. 1991 Thyroid hormones and bone mass. J Clin Endocrinol Metab. 72:1182-1183.
18. Diamond T, Nery L, Hales I. 1991 A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab. 72:1184-1188.
19. Zanatta GP, Simioni N, Girelli ME, Nacamulli D, Busnardo B. 1984 Parathyroid hormone and calcitonin in thyrotoxicosis. Horm Metab Res. 16:384-388.
20. Bijvoet OLM, Van der Sluys Veer J, Jansen AP. 1968 Effects of calcitonin on patients with Paget's disease, thyrotoxicosis and hypercalcemia. Lancet. 1:876-82.
21. Diaz-Curiel M, Castro N. 1992 Bone mineral density in the Spanish population measured by dual x-ray absorptiometry (DEXA). Bone Miner. 17(Suppl 1):133.
22. Martin-Moreno JM, Boyle P, Gorgojo L, et al. 1993 Development and validation of a food frecuency questionnaire in Spain. Int J Epidemiol. 22:512-519.
23. Overgaard K, Hansen MA, Jensen SB, Christiansen C. 1992 Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J. 305:556-561.
24. Mosekilde L, Eriksen EF, Charles P. 1990 Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am. 19:35-63.
25. Ongphiphadhanakul B, Alex S, Braverman LE, Baran DT. 1992 Excessive L-thyroxine therapy decreased femoral bone mineral densities in the male rat: effect of hypogonadism and calcitonin. J Bone Miner Res. 7:1227-1231.
26. Garnero P, Gineyts P, Riou JP, Delmas PD. 1994 Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab. 78:780-785.
27. Cumings SR, Nevitt MC, Browner WS, et al. 1995 Risk factors for hip fracture in white women. N Engl J Med. 332:767-772.